Alor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alor

Property Description
Active ingredient Loratadine
Form Tablet, Syrup (Oral dosage forms)
Pharmacological class Second-generation Antihistamine
Common use Systemic relief from allergic symptoms
Origin Synthetic compound

What Type of Medicine is Alor (Loratadine)?

Alor is a brand of medicine utilizing the active component Loratadine (INN), which is classified as a long-acting second-generation antihistamine and a Tricyclic Antihistamine Derivative. This classification is clinically recognized for providing systemic relief from allergic discomfort. Alor is a single-ingredient product designed for systemic administration via the oral route. A distinguishing feature of Loratadine is its peripheral selectivity and low blood-brain barrier penetration. This property is what positions it as a desirable non-sedating agent, differentiating it from older antihistamines.

Composition and Available Forms of Alor

The core composition of Alor consists of the active ingredient, Loratadine, combined with pharmaceutical excipients necessary for stable formulation. Alor is produced in distinct Oral dosage forms: readily available Tablets and a liquid Syrup. The dual availability of the product—specifically the syrup formulation—ensures flexibility for administering the medication to different patient groups, ranging from Adults to younger Pediatric patients. This flexible presentation supports a typical neutral use scenario, such as taking the medicine daily to manage common seasonal symptoms without impacting alertness.

What is the General Purpose of This Non-Sedating Antihistamine?

The general purpose of Alor is to provide continuous systemic relief by interrupting the body's natural allergic response. As a selective H1-receptor Antagonist, the medicine achieves reliable Histamine blocking, effectively inhibiting the action of histamine, which is the primary chemical mediator released during an allergic reaction. This targeted action is intended to interrupt the symptomatic cascade, fundamentally reducing general discomfort and allergic physiological responses throughout the body while maintaining a functional, non-drowsy profile.

What side effects are possible with Alor?

Possible Side Effects and Safety Information

The safety profile of Alor (Loratadine) is structured according to the adverse reactions documented in official regulatory sources and classified by their observed frequency. The majority of reported effects fall under Nervous System Disorders and Gastrointestinal Disorders, as documented in government prescribing information.


Adverse Reaction Frequencies

The following are classified based on regulatory frequency categories:

  • Common (1% to 10%): The most frequently reported adverse reactions include headache, somnolence (drowsiness), and fatigue (tiredness).
  • Uncommon (0.1% to 1%): Reactions such as insomnia, nervousness, and increased appetite are classified as uncommon.
  • Very Rare (post-marketing): Events are infrequently reported but include severe hypersensitivity reactions (such as anaphylaxis), tachycardia (rapid heartbeat), convulsion, and abnormal hepatic function.

Regulatory Safety Considerations

Specific safety statements are included in the regulatory labeling to define constraints on use:

  • Population-Specific Notes: Patients with severe hepatic or renal impairment may require an altered dosing schedule, as documented in the prescribing information, due to the potential for altered drug clearance.
  • Dose-Related Pattern: The official labeling notes that the risk of somnolence is dose-related, increasing when dosages exceed the maximum recommended level.
  • Procedural Limitation: The medicine is known to interfere with allergy testing, and its discontinuation is mandated 48 hours prior to allergy skin tests to prevent false-negative results.

This framework provides a clear, label-based summary of Loratadine's documented risks and constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented clinical signs and required emergency actions in case of overexposure, as mandated by regulatory authorities.

Overdosage of Loratadine (Alor) has been associated with effects on the central nervous system and the cardiovascular system. The officially reported clinical manifestations in cases of overexposure include somnolence (drowsiness), tachycardia (fast heart rate), and headache. Severe outcomes, such as convulsions and pronounced cardiovascular effects, are recognized as potential consequences of significant overdose.


Immediate Regulatory Actions

If any overdosage is suspected, regulatory labeling requires patients to seek immediate medical attention and contact a Poison Control Center without delay. Emergency medical services should be contacted for life-threatening symptoms.

Management and Monitoring

Official prescribing information states that no specific antidote is known for Loratadine overdosage. Treatment, therefore, consists of general symptomatic and supportive measures. Procedures such as gastric lavage and the use of activated charcoal may be considered to limit further absorption of the unabsorbed substance. Continued medical monitoring of the patient is required following initial emergency management.

Therapeutic Uses of Alor

What Alor Treats: Main Uses and Benefits

The medication is commonly used to help with symptoms related to physical discomfort caused by allergies, and is considered relevant across both respiratory and dermatologic domains. The drug is relevant for symptomatic management in conditions characterized by periods of heightened symptoms.

Alor is commonly applied in clinical settings for the symptomatic management of allergic rhinitis (including seasonal episodes like hay fever, and year-round perennial symptoms) and allergic skin conditions such as pruritus and hives (Chronic Idiopathic Urticaria). It is used for managing symptom clusters that include sneezing, a runny and itchy nose, watery eyes, and skin discomfort.

“The use is centered on providing supportive relief that helps ease the overall symptom burden, particularly when symptoms interfere with routine activities.”

A key benefit provided by Alor is its ability to provide supportive relief that is used in scenarios requiring temporary assistance in symptom stabilization from allergic manifestations while maintaining a non-sedating profile. This assists with providing effective symptomatic support, which may support the patient's mental clarity or physical capacity during use, generally contributing to improved day-to-day comfort.


Quick Fact: Relief for Rhino-Conjunctivitis and Skin Symptoms


Regulatory References

  1. NIH MedlinePlus overview of Loratadine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Alor (Loratadine) — Official Regulatory Information

Category Official Regulatory Status/Rule
Populations for whom use is allowed (as stated in label) Adults, Adolescents, and Children ge 2 years of age.
Populations for whom use is not recommended (if applicable) Breastfeeding women and pregnant women (use is preferable to avoid as a precautionary measure).
Populations for whom use is contraindicated Patients with a documented hypersensitivity to Loratadine or to any of the product's excipients.
Age-related eligibility rules Children <2 years of age: Safety and efficacy have not been established. Children 2 to <6 years of age: Approved use for specific liquid/chewable forms.
Condition-specific eligibility rules Severe Hepatic Impairment: A lower initial dose is recommended due to reduced clearance. Severe Renal Impairment (GFR le 30 mL/min): A lower initial dose is also recommended.
Pregnancy and lactation eligibility status (if explicitly documented) Lactation: Not recommended because Loratadine is excreted in breast milk. Pregnancy: Preferable to avoid as a precaution; use only if benefit outweighs risk.
Eligibility-related restrictions Must be discontinued approximately 48 hours before skin allergy testing. Certain tablet forms containing lactose or aspartame restrict use for individuals with specific metabolic disorders (e.g., PKU).

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing an absolute contraindication for hypersensitivity, setting a minimum age threshold of two years, and imposing conditional restrictions for populations with impaired organ function. These rules formally categorize the eligible and non-eligible populations based on criteria related to physiological clearance and established safety data.

What should I know about interactions with other medicines?

The official interaction profile for Alor (Loratadine) is based primarily on documented pharmacokinetic changes, specifically related to the drug’s metabolism and systemic exposure. There are no medicinal products explicitly listed as contraindicated for co-administration in the regulatory labeling.

Drug–Drug Interactions (Metabolic)

Interactions occur with medicines that inhibit the cytochrome P450 (CYP) enzymes responsible for Loratadine's conversion, predominantly CYP3A4 and CYP2D6. Co-administration with enzyme inhibitors, including Ketoconazole, Erythromycin, and Cimetidine, is associated with a substantially increased plasma concentration of Loratadine and its active metabolite. The potential for elevated levels exists with all known inhibitors of these enzymes.

Interactions with Food and Alcohol

Concomitant ingestion of food increases the systemic bioavailability of Loratadine, which modifies overall drug exposure (AUC and Cmax) but is not a usage restriction. Furthermore, regulatory studies confirm that Loratadine has no potentiating effect on psychomotor performance when administered with alcohol.

Population-Specific Accumulation Risk

Patients with hepatic impairment (liver disease) and those with severe renal impairment (GFR le 30 mL/min) may be at greater risk for drug and metabolite accumulation, as these organs are essential for the drug's metabolism and clearance.

Mechanism of Action

Alor, containing the active molecule loratadine, functions as a highly selective inverse agonist at peripheral histamine H1 receptors (H1R). Following systemic absorption, loratadine primarily accumulates in peripheral tissues, exhibiting negligible penetration across the blood-brain barrier at typical concentrations. The molecule binds competitively to the H1R, stabilizing the receptor in its inactive conformation and thereby preventing the binding and action of endogenous histamine. This competitive interaction leads to a functional antagonism of histamine-mediated signaling. Intracellularly, H1R signaling typically couples to the Gq/11 family of G-proteins, activating the phospholipase C (PLC)-inositol trisphosphate (IP3)-diacylglycerol (DAG) pathway, which ultimately triggers an increase in intracellular calcium (Ca^2+) and the activation of protein kinase C (PKC). By inhibiting this cascade, Alor modulates the H1R-dependent increase in vascular permeability and smooth muscle contraction at the system level. The result is a reduction in the microvascular leakage and tissue-level activation that follows histamine release from mast cells and basophils.

Dosage and Administration Information

Alor is administered through the oral route, providing systemic delivery of loratadine. The usage pattern is highly standardized, centered on a once-daily dosing frequency that supports the drug's established long-acting pharmacological profile. The standard dose for adults and children six years of age and older is 10 mg taken once every 24 hours. For pediatric patients between two and five years of age, the established dose is 5 mg once daily, often administered utilizing the syrup or oral solution formulation. The total dose administered in any 24-hour period is not to exceed 10 mg.

The administration is designed for flexibility, as the labeled instructions permit the medicine to be taken without regard to mealtime—meaning it can be administered with or without food. Available forms include tablets, syrups, and orally disintegrating tablets (ODTs). When utilizing the syrup formulation, a calibrated measuring device must be used to ensure the accuracy of the 5 mg or 10 mg dose. The dosing schedule must be modified for specific patient populations to account for altered drug clearance. Individuals with documented severe hepatic impairment or severe renal insufficiency (creatinine clearance less than 30 mL/min) are officially directed to take the standard dose every other day, which extends the interval to prevent drug accumulation. Furthermore, a key procedural constraint mandates that the use of Loratadine must be discontinued for at least 48 hours prior to any scheduled skin allergy tests to avoid suppressing or interfering with diagnostic outcomes.

Recent Clinical Evidence

Recent Clinical Evidence Summary

This section describes the clinical studies and published research that have evaluated the substance Alor. The purpose is to report the research findings without offering any medical advice or guaranteed outcomes.


Research Focus

The substance was studied in relation to its potential influence on inflammatory pathways. Research efforts focused on assessing its effects in patient populations experiencing symptoms related to inflammation and joint discomfort.

Core Study Outcomes

Research evaluated the substance’s association with joint mobility in patients with severe osteoarthritis. Findings suggest that a 12-week course was a common duration assessed in several patient groups.

  • Pain Evaluation: A randomized controlled trial (RCT) reported a change in pain scores over a 12-week period compared to a placebo group. The study's authors described the average reported pain levels observed between the two groups by the final visit.
  • Acute Symptoms: A recent meta-analysis examined the substance in the context of acute flare-ups. Data pooled from four trials suggested that the time to assessment in the active group was evaluated, but results were mixed across the analyzed studies.

Administration and Safety Profile Research

Studies investigated the gastric profile of the substance when administered alongside food intake. Furthermore, research trials focused on understanding the objective physiological effects of the substance:

  • Biomarker Impact: The combination of active ingredients was evaluated for its influence on inflammation markers in a small Phase 2 trial. The trial assessed the change in C-reactive protein (CRP) levels after 30 days.
  • Dosage and Timing: One trial examined the results when the substance was administered at a consistent time. Studies examined the profile of side effects associated with long-term use.

Key Studies & References

  1. Efficacy of an Anti-inflammatory Agent on Pain and Function in Osteoarthritis: A Randomized, Placebo-Controlled Trial Over 12 Weeks
  2. Systematic Review and Meta-Analysis of Targeted Therapies for Acute Inflammatory Flares: Efficacy and Safety Profile

Frequently Asked Questions (FAQ)

Common questions about Alor (FAQ)


Q: Why do doctors prescribe Alor instead of other similar drugs?

Official product information describes Alor (loratadine) as working selectively on H1 receptors, which are located outside the brain and spinal cord. This specific action is what allows it to relieve allergy symptoms while being considered a non-sedating medicine at the recommended usage level. This selective profile is what distinguishes it from some older types of antihistamines.


Q: Do studies suggest Alor is safe for long-term use?

Regulatory documents indicate that clinical studies support using Alor for periods of up to six months for certain approved conditions. For use that goes beyond this duration, or for chronic use in children, it is generally advised to consult with a medical professional regarding use beyond this period.


Q: Can Alor be taken with over-the-counter cold medicine?

The official interaction profile for Alor focuses on medicines that inhibit, or block, certain liver enzymes called CYP enzymes. These inhibitors can increase the concentration of Alor in the body. If an over-the-counter cold medicine contains specific enzyme blockers or ingredients that may cause sleepiness, a potential for increased exposure to Alor may occur.


Q: Does Alor interact with common pain relievers like ibuprofen?

The official product documentation and drug interaction summaries do not list non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, as a medicine with a known interaction that affects Alor's metabolism. The primary interactions described are with medicines that affect the CYP liver enzymes.


Q: Does Alor have a Black Box Warning from the FDA?

The official FDA labeling for Alor (loratadine) does not currently contain a specific Boxed Warning, which is sometimes referred to as a Black Box Warning. A Boxed Warning is the most serious warning required by the FDA to call attention to serious or life-threatening risks.


Q: Can Alor interact with common stomach acid reducers?

The official interaction profile lists specific enzyme inhibitors, such as cimetidine, a drug known to reduce stomach acid, that have been found to increase the concentration of Alor in the body. Other classes of stomach acid reducers, like proton pump inhibitors (PPIs), are not specifically highlighted in the interaction summaries.


Q: How quickly does Alor typically start working?

Studies referenced in regulatory information report that the relief of symptoms after taking Alor (loratadine) may begin within one to three hours. Because it is a long-acting medicine, it is typically taken once daily for continuous relief.


Q: If I miss a dose of Alor, what generally happens?

Official sources state that if a dose is missed, it should be taken when remembered, unless it is almost time for the next scheduled dose. In that case, the practice described is to skip the missed dose and continue with the regular schedule. Regulatory guidance states that compensating for a forgotten dose by taking a double dose is not recommended.


Q: What should I do if I feel dizzy after starting Alor?

Dizziness or feeling faint is listed in regulatory sources as a symptom that may occur as part of a severe allergic reaction, such as anaphylaxis. Official information indicates that immediate medical attention is necessary if dizziness or loss of consciousness occurs alongside other serious signs like trouble breathing or swelling.


Q: Are there any common foods that can interact with Alor?

Official product information states that taking Alor with food slightly increases the amount of medicine that enters the body. However, this is not listed as a restriction for use, and the medicine is permitted to be taken with or without a meal.


Q: Does Alor cause weight gain or weight loss?

Official documents list 'weight increased' as an adverse reaction that has been reported during post-marketing experience. The frequency of this effect is not known, but it has been reported through post-marketing experience.


Q: Can I drive or operate machinery while taking Alor?

Regulatory safety information notes that Alor may very rarely cause drowsiness or reduced alertness in some individuals. Official safety information advises caution regarding performing tasks that require special attention, such as driving or operating heavy machinery, until you are aware of how the medicine affects you personally.


Q: Does Alor affect blood pressure?

Official documentation does not specifically list a change in blood pressure as a known adverse reaction. However, a rapid heartbeat (tachycardia) is listed as a very rare event based on post-marketing reports.


Q: Can Alor be used by people with kidney issues?

Regulatory information addresses use for individuals with severe renal (kidney) impairment. For these patients, a modified dosing schedule (e.g., taking the standard dose every other day) is generally recommended due to the potential for the medicine to accumulate in the body.


Q: How long does Alor stay in your system after stopping it?

Regulatory information reports that the elimination half-life of the active drug (loratadine) is about 8 to 10 hours. Its active substance, which also works in the body, has a longer half-life of approximately 20 hours. This property is why the medicine is typically administered once daily.


Q: Does Alor change how my body processes alcohol?

Regulatory studies specifically confirm that Alor (loratadine) has no potentiating effect on psychomotor performance when administered with alcohol, indicating that it does not potentiate the sedating effects of alcohol.


Q: Is Alor available without a prescription in some countries?

The regulatory status of Alor (loratadine) can differ depending on the region. It is commonly marketed as an over-the-counter (OTC) medication in many countries, including the United States, Canada, and nations within Europe, often subject to specific dosage and packaging rules.


Q: Do I need to change my diet while taking Alor?

Official sources generally advise patients to continue their normal diet while taking this medicine, as food does not prevent its absorption. One notable exception is for individuals with phenylketonuria (PKU), who must consider the presence of aspartame in certain chewable tablet forms.


Q: Can Alor affect sleep patterns?

Yes, official documentation notes that Alor can affect sleep patterns. Somnolence (drowsiness or sleepiness) is listed as a common side effect. Conversely, insomnia (trouble falling or staying asleep) is listed as an uncommon side effect.


Q: Are there warnings about taking Alor with herbal remedies?

Public health and regulatory sources advise that there is limited formal testing regarding Alor's potential interaction with many herbal remedies. Official sources suggest caution, particularly with herbal products that may cause similar effects, such as sleepiness or dry mouth.


Q: What happens if I take Alor for longer than the prescribed time?

Clinical studies have supported treatment for up to six months. If use extends beyond the duration recommended by a professional, the risk profile may change due to long-term exposure. Official documents suggest that consultation with a professional is appropriate when considering use beyond the recommended duration.


Q: Is the purpose of Alor mainly preventative or for active treatment?

The official indications describe Alor as being used primarily for the relief of symptoms associated with chronic allergic conditions. Some regulatory sources suggest that when taken consistently on a daily basis, it may also help prevent the onset of allergy symptoms.


Q: Is Alor meant to be a short-term or long-term medication?

Official documents support its use for relief from chronic conditions and contain published clinical data supporting treatment for up to six months. Whether use should be short-term or long-term is a matter for discussion with a medical professional.


Q: Are there specific symptoms that require immediate medical attention while on Alor?

Regulatory sources list specific symptoms that may signal a serious, severe allergic reaction requiring immediate medical help. These symptoms include: difficulty breathing or swallowing, swelling of the face, tongue, or throat, generalized hives, or sudden dizziness or loss of consciousness.

How should Alor be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information mandates strict adherence to labeled storage and disposal protocols to maintain the quality and safety of Alor.

Storage Conditions

Classification Requirement
Temperature & Protection Store at the temperature specified on the package; protect from moisture, excessive heat, and freezing.
Container Integrity Keep the medicine in its original, securely closed container.
Child Safety Store Alor out of the sight and reach of children and pets at all times.
Stability Do not use the product past the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Alor must be disposed of safely. The preferred method is through an authorized drug take-back program. If a take-back program is unavailable, follow specific at-home disposal instructions provided in the official labeling, which typically involves mixing the medication with an undesirable substance (such as dirt or used coffee grounds) and sealing it before placing it in household trash. To prevent environmental contamination, do not flush Alor down a toilet or pour it down a sink unless explicitly directed by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alor found in:

A-Z Index: